A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
Status:
Recruiting
Trial end date:
2023-06-15
Target enrollment:
Participant gender:
Summary
The study is a designed to evaluate safety and activity of APG-1252 when administered as
monotherapy and in combination with ruxolitinib in previously ruxolitinib treated
myelofibrosis patients.